MAPK14 and amyotrophic lateral sclerosis: Kenpaullone has undergone preclinical development for amyotrophic lateral sclerosis (ALS)11 and its derivatives alsterpaullone and 1-azakenapaullone protected podocytes by preventing apoptosis following activation of GSK3α/β and p38 mitogen-activated protein kinase pathways12.